The hypothesis of this trial is to assess the effect of spironolactone on heart size and
Dialysis patients have significant morbidity and mortality associated with left ventricular
hypertrophy and cardiac failure. Aldosterone may have an important role in the development
of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial
effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown
significant survival benefit in a non-dialysis population with congestive heart failure.
This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on
cardiac hypertrophy in the end-stage renal disease population.
- hemodialysis patients
- non compliance
- expected survival less than 9 months